

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/701,675	07/09/2001	Olga Bandman	PF-0531 USN	8931
22428 7.	590 10/28/2004		EXAMINER	
FOLEY AND LARDNER			MERTZ, PREMA MARIA	
SUITE 500 3000 K STREET NW			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20007			1646	

DATE MAILED: 10/28/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/701,675	BANDMAN ET AL.				
•	Examiner	Art Unit				
	Prema M Mertz	1646				
The MAILING DATE of this communication appe	ears on the cover sheet with the o	correspondence addr	ess			
THE REPLY FILED 12 October 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR RE	EPLY [check either a) or b)]					
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this a no event, however, will the statutory period for reply expire ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailin S FILED WITHIN TWO MONTHS OF TI	g date of the final rejection. HE FINAL REJECTION.	on. See MPEP			
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Offit timely filed, may reduce any earned patent term adjustment. See 37 C	of extension and the corresponding amo the shortened statutory period for reply ce later than three months after the ma	ount of the fee. The appropriate of the final (opriate extension Office action; or			
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a) ☑ they raise new issues that would require further consideration and/or search (see NOTE below);						
(b) they raise the issue of new matter (see Note be	pelow);					
(c) ⊠ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: See Continuation Sheet.						
3. Applicant's reply has overcome the following rejection(s):						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:						
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.						
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w			and an			
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to:						
Claim(s) rejected: <u>44-51, 54, 58-59 and 61-62</u> .						
Claim(s) withdrawn from consideration:						
8. The drawing correction filed on is a) app	roved or b) disapproved by	the Examiner.				
9. Note the attached Information Disclosure Stateme						
10. Other:	, , , , , , , , , , , , , , , , , , , ,					
To Outor		0 4				
		Prema M Mertz Primary Examiner Art Unit: 1646				

U.S. Patent and Trademark Office PTOL-303 (Rev. 11-03) Continuation of 2. NOTE: The new limitation "wherein said polypeptide promotes or inhibits cell proliferation" in claims 44, 51, 61-62 is contradictory. Entry of the amended claims with this limitation would precipitate a 35 USC second paragraph rejection .